For more than two decades, global pharmaceutical launch strategy followed a familiar pattern. The United States came first. Europe followed later, sometimes much later, after regulatory approval, health technology assessment, and national pricing negotiations had run their course. The reasoning behind this sequencing rarely required explanation. The United States offered rapid revenue generation, relatively unconstrained pricing at launch, and a reimbursement system that gene

The re-emergence of Most Favoured Nation (MFN) style pricing policies and the broader political momentum behind international reference pricing has re-ignited a structural question for global biopharma: Does launching in Europe now carry disproportionate global pricing risk? For US-anchored manufacturers in particular, the concern is clear. If ex-US net prices cascade into US negotiations through IRA-linked discussions, reference baskets, or commercial contracting logic, then

In European commercialisation, distribution is still too often treated as an executional detail, something to be addressed once pricing, access, and clinical strategy have already been defined. That assumption quietly undermines more launches than weak data or imperfect value narratives ever do. Distribution is not about moving product efficiently through a supply chain. It is about where financial exposure sits, who carries legal accountability, and which organisation stands

Early Access Programmes are still too often treated as a necessary but temporary bridge, a way to supply patients with serious or life-threatening disease while regulatory and reimbursement processes catch up. In Europe, these programmes take many forms, from compassionate use and named-patient supply to formal cohort or national early-access schemes. What unites them is urgency: patients who cannot wait, clinicians who are prepared to act, and sponsors operating in a space o

Early access pathways occupy a deceptively powerful position in European pharmaceutical strategy. They are often discussed as regulatory mechanisms, sometimes as ethical obligations, and increasingly as tactical commercial tools. Rarely are they treated with the strategic seriousness they deserve. In principle, early access exists for a narrow and defensible reason: to ensure that patients with serious or life-threatening conditions are not denied potentially beneficial thera

For most pharma and biotech companies, Europe is framed as a commercial problem to be solved later. A launch plan to be refined. A partnership discussion to be revisited. An infrastructure question that can wait until after approval.This framing is deeply misleading. Europe is not a launch choice. It is a structural commitment. Whether a company decides to go it alone, partner, or outlicense Europe does not simply shape how a product is commercialised; it fixes the organisati

There is a persistent misunderstanding about Europe that continues to quietly destroy value for first-time Pharma and Biotech entrants. Europe is not uniquely hostile. It is not inherently slow. And it does not require scale before access. What it does require is clarity. Clarity of ownership, clarity of intent, and clarity of decision-making. Where companies fail is not in execution, but in allowing responsibility for irreversible decisions to diffuse across partners, adviso

For more than two decades, European pharmaceutical launch strategy has been built on a reassuring simplification: Europe is complex, but it is ultimately manageable as a single market. Execute a coordinated EU5 launch, align pricing corridors, navigate HTA sequentially, and scale from there. That assumption is now obsolete. By 2026, Europe will no longer fail companies because it is slow or bureaucratic. It will fail them because it is structurally fragmented in ways that inv

2025 marked a decisive inflection point for pharmaceutical and biotech commercialisation in Europe. Long-signalled reforms moved from policy design into operational reality, forcing companies to confront not just what Europe intends to do, but how it actually behaves at launch. Europe has not become simpler, but it has become more predictable for companies that plan properly. 2026 will reward those that treat evidence, policy, pricing, and access as a single integrated system